ArticlePloS one2013

First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors.

Klaus Mross et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.